Denali Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 445
- Market Cap
- -
- Introduction
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: DNL201Drug: Placebo
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT04551534
- Locations
- ๐บ๐ธ
Clinical Site(s), Dallas, Texas, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT04268784
- Locations
- ๐ณ๐ฑ
Centre for Human Drug Research (CHDR), Leiden, South Holland, Netherlands
A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT04251026
- Locations
- ๐ณ๐ฑ
Erasmus Medical Center, Rotterdam, South Holland, Netherlands
๐บ๐ธUNC Children's Research Institute, Chapel Hill, North Carolina, United States
๐บ๐ธUCSF Benioff Children's Hospital, Oakland, California, United States
A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
- Conditions
- Mucopolysaccharidosis II
- Interventions
- Other: No Intervention
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04007536
- Locations
- ๐บ๐ธ
UPMC | Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
๐บ๐ธUCSF Benioff Children's Hospital, Oakland, California, United States
๐ฌ๐งBirmingham Children's Hospital, Birmingham, United Kingdom
Study to Evaluate DNL747 in Subjects With Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- Drug: DNL747Drug: Placebo
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03757325
- Locations
- ๐ณ๐ฑ
Clinical Site(s), Groningen, Netherlands
Study to Evaluate DNL201 in Subjects With Parkinson's Disease
- Conditions
- Parkinson Disease
- Interventions
- Drug: DNL201Drug: Placebo
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT03710707
- Locations
- ๐บ๐ธ
Clinical Site(s), Spokane, Washington, United States